Atai Life Sciences N.V. (ATAI)
NASDAQ: ATAI · IEX Real-Time Price · USD
1.480
0.00 (0.00%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Atai Life Sciences Employees
Atai Life Sciences had 83 employees as of December 31, 2023. The number of employees decreased by 50 or -37.59% compared to the previous year.
Employees
83
Change (1Y)
-50
Growth (1Y)
-37.59%
Revenue / Employee
$3,337
Profits / Employee
-$407,265
Market Cap
247.76M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 83 | -50 | -37.59% |
Dec 31, 2022 | 133 | 46 | 52.87% |
Dec 31, 2021 | 87 | 52 | 148.57% |
Dec 31, 2020 | 35 | - | - |
Related Stocks
Company Name | Employees |
---|---|
AVITA Medical | 207 |
Utah Medical Products | 190 |
Cibus | 183 |
Codexis | 174 |
Senseonics Holdings | 132 |
Profound Medical | 131 |
Nanobiotix | 102 |
Zevra Therapeutics | 69 |
ATAI News
- 26 days ago - atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference - GlobeNewsWire
- 4 weeks ago - atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a - GlobeNewsWire
- 7 weeks ago - atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference - GlobeNewsWire
- 2 months ago - atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates - GlobeNewsWire
- 3 months ago - atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression - GlobeNewsWire
- 3 months ago - atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology - GlobeNewsWire
- 4 months ago - atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights - GlobeNewsWire
- 4 months ago - atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression - GlobeNewsWire